A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC).
Justin F. Gainor
No relevant relationships to disclose
Anna M. Varghese
Honoraria - Illumina (I)
Sai-Hong Ignatius Ou
No relevant relationships to disclose
Sheheryar Kabraji
No relevant relationships to disclose
Mark M Awad
No relevant relationships to disclose
Ryohei Katayama
No relevant relationships to disclose
Amanda Pawlak
No relevant relationships to disclose
Mari Mino-Kenudson
No relevant relationships to disclose
Beow Y. Yeap
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - ARIAD; Celgene; Chugai Pharma; Daiichi Sankyo; Foundation Medicine; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Concordia Pharmaceuticals; GlaxoSmithKline; Infinity; Merck; Millennium; Novartis; Pfizer
Anthony John Iafrate
Consultant or Advisory Role - Bio-Reference Laboratories
Maria E. Arcila
No relevant relationships to disclose
Marc Ladanyi
No relevant relationships to disclose
Jeffrey A. Engelman
Stock Ownership - GATEKEEPER Pharmaceuticals
Research Funding - AstraZeneca; Novartis; Sanofi
Dora Dias-Santagata
Consultant or Advisory Role - Bio-Reference Laboratories
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Novartis; Pfizer